HOUSE_OVERSIGHT_024044.jpg
2.83 MB
Extraction Summary
1
People
8
Organizations
0
Locations
0
Events
3
Relationships
3
Quotes
Document Information
Type:
Investment memorandum / fund strategy document
File Size:
2.83 MB
Summary
This document is page 33 of a confidential investment memorandum for a fund named 'New Leaf' (likely New Leaf Venture Partners). It details the fund's strategy regarding late-stage commercialization and small-cap public biotech companies, citing specific successful exits like Acadia Pharmaceuticals (2.5x) and InterCept Pharmaceuticals (3.2x), as well as a recapitalization of MEI Pharma. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained during a congressional investigation, likely into financial networks connected to the broader Epstein inquiry.
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Investment Managers |
Responsible for tracking companies and making investment decisions for the New Leaf fund.
|
Organizations (8)
| Name | Type | Context |
|---|---|---|
| New Leaf |
The entity whose investment strategy is described; likely New Leaf Venture Partners.
|
|
| Acadia Pharmaceuticals |
NLV-II investment, NASDAQ: ACAD, exited at 2.5x.
|
|
| Durata Therapeutics |
NLV-II investment, NASDAQ: DRTX, spun out of Pfizer.
|
|
| Pfizer |
Original owner of the program that became Durata Therapeutics.
|
|
| InterCept Pharmaceuticals |
NLV-II investment, NASDAQ: ICPT, exited at 3.2x.
|
|
| MEI Pharma |
NLV-II investment, NASDAQ: MEIP, recapitalized by the Fund.
|
|
| S*Bio |
Previous owner of the asset Pracinostat before MEI Pharma.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024044'.
|
Relationships (3)
Examples of this type of later stage investment in the New Leaf portfolio include Acadia Pharmaceuticals
investment the Fund Managers made to recapitalize the company
Durata Therapeutics... spun out of Pfizer
Key Quotes (3)
"Fund will seek to fund companies much later into commercialization to the point of sustainable profitability."Source
HOUSE_OVERSIGHT_024044.jpg
Quote #1
"New Leaf’s focus on investment opportunities in small capitalization public biotech companies leverage the broad investment capabilities within the firm"Source
HOUSE_OVERSIGHT_024044.jpg
Quote #2
"The Fund will generally look to source or augment transformative, structured transactions in public companies, where a New Leaf partner will have the opportunity to join the board of directors."Source
HOUSE_OVERSIGHT_024044.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document